CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).

R. Smith, Matthew; Matsubara, Nobuaki; R. McKay, Rana; M. Piulats, Josep; Todenhöfer, Tilman; Zhang, Tian; Fasnacht, Nicolas; Sherwood, Sarah; Johnston, Erica; Schaverien, Clare; Lithio, Andrew; Nacerddine, Karim; Agarwal, Neeraj

doi:10.1200/jco.2023.41.6_suppl.tps289

Public

CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).

Shared by NobleBlocks on Feb 20, 2023 • 12:00 AM UTC

Authors:

Matthew R. Smith

Nobuaki Matsubara

Rana R. McKay

Abstract

TPS289 Background: Landmark trials have established a survival benefit for novel hormonal agents (NHA) added to androgen deprivation therapy (ADT) for mHSPC. Yet, there is a significant medical need to expand therapeutic options, especially for pts with high-risk mHSPC who experience poorer outcomes...

Subject

Medicine

Clinical endpoint

Prostate cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!